Literature DB >> 15893448

In vitro models to evaluate acute and chronic injury to the heart and vascular systems.

Charles R Partridge1, Charles D Johnson, Kenneth S Ramos.   

Abstract

Multiple in vitro model systems are currently available to evaluate structure and function relationships in the cardiovascular system as well as the system's response to injury. As the level of molecular sophistication continues to advance, so does the level of complexity of the analysis. One of the most daunting tasks faced by researchers interested in studying cardiovascular function and injury is the selection of the system or systems best suited to answer the particular question at hand. In order to successfully apply any given model system, the researcher must recognize the advantages and limitations in the system of choice. This review provides a listing of the historical and modern techniques used to study cardiovascular function and chemically-induced toxicity. With the growing number of new pharmaceuticals discovered each year, it is imperative to use experimental model systems that allow for identification of targets that participate in or mediate adverse outcomes. Clearly, in vitro analysis cannot replace in vivo experimentation, but the methods currently available allow for a reduction in the number of animals used for experimentation and a better understanding of the complexity associated with the injury response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893448     DOI: 10.1016/j.tiv.2005.03.009

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  3 in total

Review 1.  Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation.

Authors:  Stacey J Coleman; Jennifer Watt; Prabhu Arumugam; Leonardo Solaini; Elisabeta Carapuca; Mohammed Ghallab; Richard P Grose; Hemant M Kocher
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 2.  How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

Authors:  Hg Laverty; C Benson; Ej Cartwright; Mj Cross; C Garland; T Hammond; C Holloway; N McMahon; J Milligan; Bk Park; M Pirmohamed; C Pollard; J Radford; N Roome; P Sager; S Singh; T Suter; W Suter; A Trafford; Pga Volders; R Wallis; R Weaver; M York; Jp Valentin
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

3.  Biological Effects of Clinically Relevant CoCr Nanoparticles in the Dura Mater: An Organ Culture Study.

Authors:  Iraklis Papageorgiou; Thomas Abberton; Martin Fuller; Joanne L Tipper; John Fisher; Eileen Ingham
Journal:  Nanomaterials (Basel)       Date:  2014-06-16       Impact factor: 5.076

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.